acute myocardial infarction | taspoglutide | not classified | versus placebo No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
HEBE III, 2010 | epoetin alfa vs placebo | | | MACE 0.48 [0.22; 1.04] Cardiovascular death 0.51 [0.05; 5.54] Emergency PCI for in-stent thrombosis/reinfarction/unstable angina 0.56 [0.19; 1.65] Stroke 1.01 [0.06; 16.09] Heart failure 0.14 [0.02; 1.17] |
Trial | Treatments | Patients | Method |
---|
HEBE III, 2010 | single bolus of 60,000 IU epoetin alfa administered intravenously within three hours after a successful PCI (n=263) vs. control (n=266) | patients with a first ST-elevation MI and a successful PCI | open Parallel groups Sample size: 263/266 Primary endpoint: left ventricular ejection fraction FU duration: 6 weeks |
|